SOURCE: CymaBay Therapeutics

CymaBay Therapeutics Logo

February 25, 2014 09:00 ET

CymaBay Therapeutics to Present at Cowen and Roth Investor Conferences

NEWARK, CA--(Marketwired - February 25, 2014) - CymaBay Therapeutics, Inc. (OTCQB: CYMA) today announced that Harold Van Wart, President and Chief Executive Officer, will present an overview of the company at investment conferences hosted by Cowen and Company and ROTH Capital Partners.

Cowen and Company 34th Annual Health Care Conference
March 5-7
The Boston Marriott Copley Place, Boston, MA

CymaBay Presentation
Monday, March 3
4:50 - 5:20 p.m. EST

A live and archived webcast of CymaBay's presentation at the Cowen conference will be accessible on CymaBay's website at http://www.cymabay.com

ROTH 26th Annual Conference
March 9-12
The Ritz Carlton, Laguna Niguel, CA

CymaBay Presentation
Monday, March 10
3:00 - 3:30 p.m. PST

About CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease.

For additional information about CymaBay visit www.cymabay.com.

Contact Information